Endourology

Effects of Tamsulosin, Solifenacin, and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts

Kyoung Taek Lim, Yong Tae Kim, Tchun Yong Lee, Sung Yul Park
Department of Urology, Hanyang University College of Medicine, Seoul, Korea

Purpose: To evaluate the effect of tamsulosin, solifenacin, and combination therapy of two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.

Materials and Methods: A total of 168 patients underwent placement of a double-J ureteral stent after retrograde ureteroscopy for urinary stone disease. All patients received polyurethane double-J ureteral stents (6 Fr, 24 or 26 cm), which were removed a mean of 14 days postoperatively. A total of 48 patients were given no medication (Group 1), 43 patients were given tamsulosin 0.2 mg once daily (Group 2), 45 patients were given solifenacin 5 mg once daily (Group 3), and 32 patients were given a combination of two agents postoperatively (Group 4). International Prostate Symptom Score/quality of life (IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires were completed by each patient at 1 day postoperatively and on the day of stent removal.

Results: In the total group of patients, the mean age was 50.24±12.90 years. There was a significant difference in the IPSS total score between group 1 and groups 3 and 4. Group 4 also differed significantly from group 1 in the irritative subscore. The obstructive subscore differed between groups 2 and 4 and group 1. There was a statistically significant difference between group 1 and group 4 in the QoL score. There were no significant differences in the VAPS.

Conclusions: Combination therapy with tamsulosin and solifenacin improved both irritative and obstructive symptoms more than in the other groups. Combination therapy should be strongly considered for patients who complain of stent-related symptoms.

Key Words: Pain; Stents; Ureter

INTRODUCTION

Ureteral stents, which were introduced by Zimskind et al in 1967, are widely used for urinary tract disease [1]. The double-J stent, which is the most common form of ureteral stent, is used in obstructive pyelonephritis, intolerable acute renal colic, ureteral edema, ureter perforation following endoscopic procedures, and diseases such as steinstrasse [2,3].

Despite the usefulness of stents, however, patients experience various stent-related symptoms, such as pain, frequency, and urgency, which cause a significant decrease in patient health-related quality of life (HRQoL) [4]. The etiology of these symptoms is unknown. Thomas reported that an important factor of stent-related symptoms is the pressure transmitted to the renal pelvis during urination and trigonal irritation by the intravesicular part of the stent [5]. For this reason, several attempts to minimize stent-related symptoms have recently been reported. Pharmacologic management is one such trial, especially the prescription of selective alpha-1-blockers and antimuscarinic agents. We believe that pharmacologic management is simpler and less invasive than other ways. The purpose of this article was therefore to analyze and assess the effectiveness of a selective alpha-1-blocker (tamsulosin) and antimuscarinic (solifenacin) in improving the lower urinary tract symp-
toms of patients with indwelling double-J ureteral stents.

**MATERIALS AND METHODS**

1. **Materials**

Between January 2010 and December 2010, 168 patients (108 men and 60 women) underwent double-J stenting retrogradely after retrograde ureteroscopy for urinary stones by a single surgeon. Patient data were obtained retrospectively through chart review. Patients who were previously diagnosed with benign prostate hyperplasia or overactive bladder and who were prescribed a selective alpha-1-blocker or antimuscarinic agent were excluded from this study. In addition, patients who were using analgesics before surgery were also excluded. The ureteral stent was composed of polyurethane material and its diameter was 6 Fr; the lengths were 24 cm and 26 cm. The length of ureteral stent was dependent on the patient’s height.

2. **Methods**

Surgery was performed under general anesthesia and the position of the stent was confirmed by plain X-ray. The stents were removed 14 days after surgery. The patients were divided into four groups. Group 1 (n=48) was the control group and did not take any drugs. Group 2 (n=43) received tamsulosin 0.2 mg once a day every day. Group 3 (n=45) received solifenacin 5 mg once a day every day. Group 4 (n=32) received tamsulosin 0.2 mg and solifenacin 5 mg daily. The day before surgery, on postoperative day 1, and on the day of stent removal, each patient completed written International Prostate Symptom Score/quality of life (IPSS/QoL) and visual analogue pain scale (VAPS) questionnaires. The IPSS was divided into the total score, obstructive symptom score, and irritative symptom score, and each was compared. Each group’s preoperative day, postoperative day, and stent removal day scores were compared. Chi-square test, one-way ANOVA, and one-way repeated-measures ANOVA were used for comparisons between each of four groups. Values of p < 0.05 were considered statistically significant. Statistical analyses were performed with SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

The mean age of the patients was 50.24±12.90 years, and there were no significant differences between the groups. A total of 103 patients has lower ureter stones, whereas 18 patients had mid ureter stones. The stone distribution was significantly different in each group (p < 0.001) (Table 1). There were statistically significant differences in the IPSS total score and the obstructive subscore by one-way repeated-measures ANOVA (p=0.013, 0.006). There were significant differences between group 1 and group 4 (p=0.015), and between group 2 and group 4 (p=0.031), in the IPSS total score. For the obstructive subscore, group 4 differed significantly from group 1 (p=0.003). There were no statistically significant differences in the irritative subscore, QoL, or VAPS (p=0.075, 0.068, and 0.088, respectively). However, the p-value of interaction was statistically significant for the IPSS total score, irritative subscore, obstructive subscore, and QoL (p < 0.001, < 0.001, 0.015, and 0.012, respectively).

We therefore compared each group by one-way ANOVA at each time point. On the day of stent removal, all scores were significantly different in each group except the VAPS (p < 0.001, < 0.001, < 0.001, < 0.001). In particular, all scores were significantly lower in group 4 except for VAPS. In group 2, only the obstructive score was significantly lower. The total and irritative subscore were significantly lower in group 3. Preoperatively and 1 day postoperatively, there were no significant differences in any group. The VAPS did not appear to significantly change in any groups (Table 2). According to the multiple comparison test on the day of stent removal, there was a significant decrease only in group 4. This suggests that that stent-related symptoms improved more in group 4 than in group 1. Symptoms did not significantly improve in the other groups.

The side effects of tamsulosin and solifenacin were minimal. No patients discontinued the medication because of side effects.

**DISCUSSION**

Ureteral stents can be used variously in the management of patients with indwelling double-J ureteral stents.

---

**TABLE 1. The characteristics of 168 patients**

|                  | Group 1          | Group 2          | Group 3          | Group 4          | p-value*   |
|------------------|------------------|------------------|------------------|------------------|------------|
| Patient (n)      | 48               | 43               | 45               | 32               | 0.986      |
| Age‡ (yr)        | 50.08±11.47      | 49.91±15.23      | 49.87±13.29      | 50.72±11.46      | 0.564      |
| Gender           |                  |                  |                  |                  | <0.001     |
| Male             | 31               | 24               | 31               | 22               |            |
| Female           | 17               | 19               | 14               | 10               |            |
| Stone location   |                  |                  |                  |                  |            |
| Upper ureter     | 7                | 12               | 14               | 14               |            |
| Mid ureter       | 5                | 0                | 3                | 10               |            |
| Lower ureter     | 36               | 31               | 28               | 8                |            |

*: chi-square test, ‡: Mean±SD
of urinary tract diseases. For example, for the prevention of ureteral obstruction and recovery of damaged ureter tissue, narrowing the expansion of the ureter and the stone will help with emissions [2]. Ureteroscopy, especially after ureteroscopic lithotripsy, routinely make use of ureteral stents [6]. The use of ureteral stents aids in the improvement of urinary tract disease, whereas patients with indwelling stents have been known to complain of a variety of stent-related symptoms. In fact, flank pain, lower abdominal pain or loin pain, frequency, urgency, infection, and hematuria are known stent-related symptoms [7]. Joshi et al reported that, because of these stent-related symptoms, 80% of patients have a reduced HRQoL and need continued understanding and interest about their symptoms [8]. To solve these problems, studies have been run in several ways. First, stent material changes have been tried to reduce the symptoms. For example, double-J stents with a tapered distal end made with a hydrophilic material were introduced [9]. In addition, studies about the relationship between stent length and morbidity have been reported. If a ureteral stent is needed after endoscopic surgery, ureteral length should be measured so that an appropriate stent can be used in patients, which can reduce distal migration and stent-related symptoms [10]. Periureteral injection of botulinum toxin type A after stent insertion has been shown to decrease pain and narcotic requirement [11].

We believe that new stent development is difficult. In addition, the cost and technical difficulties of botulinum toxin treatment are considered to be problems. We therefore sought safe and convenient ways to improve stent-related symptoms and we researched pharmacologic management as one of those ways. Stent-related symptoms are similar to the benign prostatic hyperplasia symptoms caused by urethral and bladder resistance and bladder instability [12]. For this reason, some studies have reported that selective alpha-1-blockers improve stent-related symptoms. Beddingfield et al reported that patients taking alfuzosin 10 mg daily had improved frequency and flank pain [13]. Furthermore, improvement of sleep disorders and daily life were also reported. Deliveliotis et al reported that alfuzosin improved stent-related symptoms and pain as well as sexual function and general health [14]. Wang et al suggested that the selective alpha-1-blocker tamsulosin improved urinary symptoms, flank pain, and pain during voiding [15]. In addition, Damiano et al reported that the administration of tamsulosin improved urinary symptoms, VAPS, and QoL [12]. In our study, the IPSS total score, irritative subscore, QoL, and VAPS did not show statistically significant differences. However, the difference in the obstructive subscore was statistically significant.

Stent-related symptoms are similar to overactive bladder symptoms (urinary frequency, urgency, and urge incontinence) caused by involuntary bladder contraction mediated by muscarinic receptors [16]. Antimuscarinic agents have been used to improve overactive bladder symptoms. Norris et al reported that there were no significant differences between an oxybutynin-treated group and a placebo group [17]. But those authors argued that further ongoing research is needed. Agarwal et al reported that bladder discomfort was improved in an oxybutynin or

Korean J Urol 2011;52:485-488

### Table 2. Comparisons of IPSS/QoL and VAPS in group 1, 2, 3 and 4

| Symptom            | Group 1 | Group 2 | Group 3 | Group 4 | p-value<sup>a</sup> | p-value<sup>b</sup> |
|--------------------|---------|---------|---------|---------|----------------------|----------------------|
| IPSS score         |         |         |         |         |                      |                      |
| Preoperative       | 8.94±4.13 | 8.60±4.12 | 9.04±3.94 | 8.72±4.16 | 0.958                |                      |
| On one day postoperatively | 11.65±4.38 | 12.53±4.79 | 11.16±5.13 | 11.47±5.98 | 0.013 (<0.001)<sup>f</sup> | 0.552                |
| On the day of stent removal | 13.77±4.50 | 12.77±5.24 | 11.04±5.29 | 7.16±3.37 | <0.001               |                      |
| T<sub>d</sub>       | 1       | 1, 2    | 2       | 3       |                      |                      |
| IPSS irritative subscore |         |         |         |         |                      |                      |
| Preoperative       | 4.15±2.59 | 4.30±2.84 | 4.49±3.09 | 4.84±2.71 | 0.735                |                      |
| On one day postoperatively | 6.44±3.46 | 7.79±3.69 | 6.27±4.00 | 7.09±5.52 | 0.075 (<0.001)<sup>f</sup> | 0.201                |
| On the day of stent removal | 7.48±3.50 | 8.05±3.88 | 5.73±4.00 | 4.22±2.70 | <0.001               |                      |
| T<sub>d</sub>       | 1, 2    | 1       | 2, 3    | 3       |                      |                      |
| IPSS obstructive subscore |         |         |         |         |                      |                      |
| Preoperative       | 4.79±3.16 | 4.30±2.95 | 4.56±2.78 | 3.88±2.88 | 0.572                |                      |
| On one day postoperatively | 5.21±2.57 | 4.74±2.91 | 4.89±2.73 | 4.38±2.54 | 0.006 (0.015)<sup>f</sup> | 0.592                |
| On the day of stent removal | 6.29±2.63 | 4.72±3.24 | 5.31±2.91 | 2.94±2.06 | <0.001               |                      |
| T<sub>d</sub>       | 1, 2    | 1       | 2, 3    | 3       |                      |                      |
| QoL                |         |         |         |         |                      |                      |
| Preoperative       | 2.52±1.79 | 2.19±1.80 | 2.42±1.62 | 1.88±1.77 | 0.385                |                      |
| On one day postoperatively | 2.21±1.76 | 2.44±1.71 | 2.51±1.74 | 2.34±1.56 | 0.068 (0.012)<sup>f</sup> | 0.844                |
| On the day of stent removal | 2.83±1.72 | 3.07±1.67 | 2.87±1.77 | 1.47±1.44 | <0.001               |                      |
| T<sub>d</sub>       | 1, 2    | 1       | 1, 2    | 2       |                      |                      |
| VAPS               |         |         |         |         |                      |                      |
| Preoperative       | 6.42±1.71 | 6.60±1.59 | 6.18±1.70 | 6.28±1.65 | 0.088 (0.634)<sup>f</sup> |                      |
| On one day postoperatively | 2.56±1.47 | 2.88±1.50 | 2.69±1.46 | 2.44±1.37 | <0.001               |                      |
| On the day of stent removal | 2.90±1.65 | 3.67±1.94 | 2.87±1.87 | 2.69±1.31 |                      |                      |

IPSS/QoL: International Prostate Symptom Score and Quality of Life, VAPS: Visual analogue pain scale, <sup>a</sup>: one-way repeated measures ANOVA, <sup>b</sup>: one-way ANOVA, <sup>c</sup>: p-value of interaction, <sup>f</sup>: the same letters indicate non-significant differences between groups based on Tukey’s multiple comparison test.
tolterodine administration group compared with a placebo group before surgery [18]. In our study, the solifenacin 5 mg daily group had statistically significant differences in the total score and irritative subscore. The other scores were not significantly different.

Lee et al compared combination treatment with tamsulosin and tolterodine with a placebo group [19]. Each group showed no significant differences in the IPSS or VAPS. They reported that correct stent location was more effective for the improvement of stent-related symptoms. In the present study, however, IPSS and QoL showed statistically significant differences in the tamsulosin and solifenacin combination treatment group. However, there was no significant difference in the VAPS.

The limitations of this study are as follows. Some patients did not complete the ureteral stent symptom questionnaire on the preoperative day. Therefore, we could not use this questionnaire. The small groups of each scale made it difficult to verify the statistical significance. Because this was a nonrandomized and retrospective study, we did not get useful and entirely credible information. Therefore, further large-scale, randomized, prospective study is needed to get more accurate information.

CONCLUSIONS

Combination therapy with tamsulosin and solifenacin improved obstructive and irritative symptoms and QoL more than in the control group. Therefore, combination therapy with tamsulosin and solifenacin should be strongly considered for patients who complain of stent-related symptoms. In the future, large-scale, prospective, and randomized study will be needed.

Conflicts of Interest

The authors have nothing to disclose.

REFERENCES

1. Zinaskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967;97:840-4.
2. Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol 2004;14:111-5.
3. Jeong H, Kwak C, Lee SE. Ureteric stenting after ureteroscopy for ureteric stones: a prospective randomized study assessing symptoms and complications. BJU Int 2004;93:1032-4.
4. Joshi HB, Stainthorpe A, Keeley FX Jr, MacDonagh R, Timoney AG. Indwelling ureteral stents: Evaluation of quality of life to aid outcome analysis. J Endourol 2001;15:151-4.
5. Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol 1993;7:137-40.
6. Halebian G, Kijivikai K, de la Rosette J, Preminger G. Ureteral stenting and urinary stone management: a systematic review. J Urol 2008;179:424-30.
7. el-Faqih SR, Shamsuddin AB, Chakrabarti A, Attassi R, Kardar AH, Osman MK, et al. Polyurethane internal ureteral stents in treatment of stone patients: morbidity related to indwelling times. J Urol 1991;146:1487-91.
8. Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 2003;169:1065-9.
9. Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol 2003;17:195-9.
10. Jeon SS, Choi YS, Hong JH. Determination of ideal stent length for endourologic surgery. J Endourol 2007;21:906-10.
11. Gupta M, Patel T, Xavier K, Marullo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol 2010;183:596-602.
12. Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D’Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol 2008;22:651-6.
13. Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 2009;181:170-6.
14. Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology 2006;67:35-9.
15. Wang CJ, Huang SW, Chang CH. Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 2009;37:147-52.
16. Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. J Endourol 2009;23:1913-7.
17. Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology 2008;71:792-5.
18. Agarwal A, Dhiraaj S, Singhal V, Kapoor R, Tandon M. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Br J Anaesth 2006;96:377-80.
19. Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, et al. Stent position is more important than alpha-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: a prospective randomized study. Korean J Urol 2010;51:636-41.